[Epoch Times, July 16, 2021]The University of Hong Kong’s School of Public Health recently published a study in “Needle Microorganisms”, showing that among the medical staff undergoing testing, the antibody level of two doses of forbidden vaccination was higher than that The two doses of Kexing vaccine were about nine times higher. Even with the first dose of Fubitai, the antibody level is higher than the two doses of Kexing.
The research was led by the Hong Kong pandemic and biostatistics professor Gao Benen, recruited 1,442 medical staff, using two methods, including enzyme-linked immunosorbent assay (ELISA) and plaque reduction neutralizing antibody test (PRNT), analysis The ability of antibodies to adhere to viruses and to prevent viruses from infecting cells.
Radio Free Asia reported that the HKU research team has initially completed the data analysis of 93 of them, of which 63 were vaccinated with Fubitel and 30 were vaccinated with Kexing. The results showed that after the first dose of Fubitai, the antibody level has risen significantly, and after the second dose is completed, the antibody level rises again; but after the first dose of Kexing, the antibody level is very low, and after the second dose, the antibody level is medium.
The research team analyzed the situation one month after vaccination and compared the data with 12 people from each of the two vaccines. It was found that 12 people who received two doses of Fubital had an average antibody level of 269 in the first month, but those who received two doses of Kexing , The antibody level is only 27, the difference is nearly nine times higher; for those who received the first dose of Fubitai, the antibody level has reached 49, but the average antibody level of Kexing is only 7.
According to Deutsche Welle, Fubitai is an mRNA Chinese virus (Wuhan virus, COVID-19) vaccine developed by the German vaccine company BioNTech. It is called BNT162b2 in Greater China (Mainland China, Hong Kong and Macau), and is called BNT162b2 in Taiwan. BNT.
Editor in charge: Zhao Fenghua #
.